Form 4: Cocrystal Pharma Director Granted Stock Options

Cocrystal Pharma, Inc. director Anthony J. Japour was granted 16,410 non-qualified stock options with an exercise price of $1.1.

Summary

• Anthony J. Japour, a Director of Cocrystal Pharma, Inc. (COCP), was granted 16,410 non-qualified stock options.
• The transaction date for this grant was January 9, 2026.
• The exercise price for these stock options is $1.1 per share.
• The options were granted under the Issuer's 2025 Equity Incentive Plan.
• The grant was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3, as it was approved by the Issuer's Compensation Committee of the Board of Directors.
• Vesting of the options is conditional on Mr. Japour continuing to serve as a director.
• One-half of the options will vest and become exercisable on January 9, 2027.
• The remaining half will vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027.
• The expiration date for these stock options is January 9, 2036.

Sentiment

Score: 6

Explanation: This filing reports a standard compensation event for a director, which is generally viewed as neutral to slightly positive as it aligns management interests with shareholders. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The compensation structure encourages the director's continued service to the company through a vesting schedule.

Negatives

• The issuance of new stock options, if exercised, could lead to a slight dilution of existing shareholder equity, although the amount is relatively small in this instance.

Risks

• The exercisability of the non-qualified stock options is subject to the execution of the Issuer's form of Non-Qualified Stock Option Agreement.
• The vesting of the options is contingent upon the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Future Outlook

The vesting schedule for the granted stock options extends through 2027, indicating a planned long-term incentive for the director's continued service and alignment with the company's future performance.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including Cocrystal Pharma, Inc., serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize performance and retention.
• The vesting schedule, with an initial tranche and subsequent quarterly installments, is a typical structure designed to ensure continued commitment over several years, comparable to practices at peer companies in the biopharma space.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized director performance.
• Director (Anthony J. Japour): Receives equity compensation, aligning personal financial interests with company performance and providing an incentive for continued service.

Next Steps

• Execution of the Issuer's form of Non-Qualified Stock Option Agreement by the reporting person.
• Vesting of one-half of the options on January 9, 2027, subject to continued service.
• Commencement of quarterly vesting installments for the remaining options starting March 31, 2027, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine grant of stock options to a director as part of their compensation. Such a transaction is a standard corporate practice aimed at aligning director interests with shareholders and does not typically provide new information that would warrant a change in investment recommendation for Cocrystal Pharma, Inc. The filing does not reveal any material operational, financial, or strategic developments that would significantly impact the company's valuation or future prospects.

Keywords

Cocrystal Pharma, COCP, stock options, director compensation, equity incentive plan, insider transaction, Form 4, corporate governance